Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review

Keyphrases

• Metabolic Complications 100%
• Antiretroviral Therapy 100%
• Protease Inhibitors 100%
• Lipodystrophy 100%
• Highly Active Antiretroviral Therapy (HAART) 66%
• Dyslipidemia 66%
• HIV-associated Lipodystrophy Syndrome 66%
• High Dose 33%
• Number of Patients 33%
• Metformin 33%
• Metabolic 33%
• Antidiabetic 33%
• Insulin Resistance 33%
• Lipoatrophy 33%
• Morphological Changes 33%
• Body Shape 33%
• Metabolic Parameters 33%
• Resistance Exercise 33%
• Nucleoside Reverse Transcriptase Inhibitors 33%
• Antiretroviral Regimens 33%
• Recombinant Human Growth Hormone Therapy 33%
• Switching Study 33%
• Parameter Shape 33%
• Switch Therapy 33%
• Therapeutic Focus 33%
• Glitazones 33%
• Shape Change 33%

Medicine and Dentistry

• Antiretroviral Therapy 100%
• Proteinase Inhibitor 100%
• Lipodystrophy 100%
• Morphology 66%
• Dyslipidemia 66%
• Highly Active Antiretroviral Therapy 66%
• HIV-associated Lipodystrophy 66%
• Reverse-Transcriptase Inhibitor 66%
• Hormone Therapy 33%
• Glycon 33%
• Antidiabetic Agent 33%
• Drug Megadose 33%
• Resistance Training 33%
• Insulin Resistance 33%
• Lipoatrophy 33%
• Human Growth Hormone 33%
• Glitazone Derivative 33%
• Metabolic Therapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Proteinase Inhibitor 100%
• Lipodystrophy 100%
• Dyslipidemia 66%
• HIV Associated Lipodystrophy 66%
• RNA Directed DNA Polymerase Inhibitor 66%
• Endocrine Therapy 33%
• Antidiabetic Agent 33%
• Metformin 33%
• Lipoatrophy 33%
• Human Growth Hormone 33%
• Insulin Resistance 33%
• Glitazone Derivative 33%